Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Nov 26, 2023; 11(33): 7972-7979
Published online Nov 26, 2023. doi: 10.12998/wjcc.v11.i33.7972
Table 1 General data, n (%) or mean ± SEM
Factors
Control group (n = 52)
Observation group (n = 56)
χ2/t
P value
Age (yr)43.85 ± 8.2342.98 ± 8.300.5460.586
Sex (male/female)28/2433/230.2830.595
Time of onset (d)3.06 ± 0.463.20 ± 0.621.3240.188
Lower limb muscle strength (grade 0-1/grade 2-3)26/2630/260.1380.711
Marital status (married/single)35/1729/272.6910.101
Table 2 Therapeutic effect, n (%)
Factors
Control group (n = 52)
Observation group (n = 56)
χ2
P value
Cured17 (32.69)24 (42.86)--
Marked response14 (26.92)20 (35.71)--
Response7 (13.46)6 (10.71)--
Nonresponse14 (26.92)6 (10.71)--
Total38 (73.08)50 (89.29)4.6950.030
Table 3 Occurrence of adverse events, n (%)
Factors
Control group (n = 52)
Observation group (n = 56)
χ2
P value
Rash2 (3.85)1 (1.79)--
Gastrointestinal discomfort2 (3.85)1 (1.79)--
Dyslipidemia4 (7.69)2 (3.57)--
Osteoporosis3 (5.77)0 (0.00)--
Total11 (21.15)4 (7.14)4.4260.035